RxDoctor Payments Data

Christopher Gakwa

Psychiatric/Mental Health · Boise, IDNPI 1205355831

Payments from drug & device makers

$1,089in general payments, 2019–2025

Across 52 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$322
  • Otsuka America Pharmaceutical, Inc.$225
  • E.r. Squibb & Sons, L.L.C.$124
  • AbbVie$101
  • Johnson & Johnson$75
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • plus $182 from 6 others

What the payments were for

  • Food & beverage$1,04296%
  • Education$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,089 in reported general payments places this provider in the 60th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$20,396
Medicare patients
51
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate63$230,528
Invega TrinzaPaliperidone Palmitate20$171,376
VraylarCariprazine Hcl63$91,030
AustedoDeutetrabenazine18$67,560
RexultiBrexpiprazole31$48,355
Paliperidone ErPaliperidone54$42,379
AristadaAripiprazole Lauroxil11$38,058
Aripiprazole127$23,652
Lurasidone Hcl74$10,610
BelsomraSuvorexant23$9,836
Fluphenazine Hcl34$8,875
Clozapine129$7,809
VyvanseLisdexamfetamine Dimesylate12$4,828
Focalin XrDexmethylphenidate Hcl20$4,743
Olanzapine138$4,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$75$401,90383 claims
AbbVieVraylar$101$91,03063 claims
Teva Pharmaceuticals USA, Inc.Austedo$14$67,56018 claims
Otsuka America Pharmaceutical, Inc.Rexulti$225$48,35531 claims
Alkermes, Inc.Aristada$31$38,05811 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$30$4,82812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →